期刊文献+

扩张型心肌病患者高尿酸血症和血浆BNP水平的关系及意义 被引量:1

The relationship of plasma BNP and uric acid level in dilated cardiomyopathy patient
原文传递
导出
摘要 目的:探讨扩张型心肌病患者高尿酸血症和血浆BNP水平的关系及意义。方法:采用化学发光法测定41例扩张型心肌病患者及30例健康对照者血浆BNP水平同时采用酶法测定其血尿酸水平。对扩张型心肌病患者按心功能恶化程度及血尿酸水平分组,对各组间血浆BNP水平进行统计学处理。结果:扩张型心肌病患者血浆BNP及血尿酸水平均显著高于对照组(P<0.01),且按心功能恶化程度逐级上升。高尿酸血症组的血浆BNP水平明显高于尿酸正常组(P<0.05)。结论:扩张型心肌病患者血浆BNP及血尿酸水平升高,且随着患者心功能分级的恶化而逐级升高,血浆BNP及尿酸水平可协同作为扩张型心肌病患者心功能分级及疗效评价的指标。 Objective:To explore the relationship of serum uric acid and plasma BNP level in dilated cardiomyopathy patients.Methods: The plasma BNP level was measured in 41 cases of dilated cardiomyopathy patients and 30 healthy people by chemiluminescene method.The serum uric acid level was measured by enzymatic method at the same time.The dilated cardiomyopathy patients were separated into groups according to the cardiac disfunction degree and serum uric acid level,and the plasma BNP level was analysed amony these groups by statistical methods.Results: The plasma BNP and serum uric acid level in dilated cardiomyopathy disease group were higher than healthy group significantly(P0.01),and increasing with the degree of cardiac disfunction.The BNP level in hyperuricemia group was higher than control group(P0.05).Conclusion: The plasma BNP and serum uric acid level increased in the dilated cardipmyopathy patients with the degree of cardiac disfuntion.They were good auxiliary indicators on cardic funtion classification and treatment effect estimation.
出处 《中国卫生检验杂志》 CAS 2010年第10期2509-2510,共2页 Chinese Journal of Health Laboratory Technology
关键词 高尿酸血症 扩张型心肌病 B型钠尿肽 尿酸 Hyperuricemia Dilated cardiomyopathy disease BNP Uric acid
  • 相关文献

参考文献5

二级参考文献12

  • 1平成斌,陈冠容.别嘌醇的药理作用及其临床新用途[J].中国社区医师,2007,23(3):19-20. 被引量:12
  • 2Harrison A, Morrison LK, Krishnaswamy P, et al. B - type natriureticpeptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Em erg Med, 2002; 39 : 131 - 138
  • 3Yasue H, YoshimuraM, Sumida H, et al. Localization and mechanism of secretion of B - type natriuretic peptide in comparison with those of A - type natriuretic peptide in normal subjects and patients with heart failure. Circulation, 1994 ;90 : 195 - 203
  • 4Groenning BA, Nillsson JC, Sondergaard L, et al. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentratrions. European Journal of heart failure, 2001 ;3:699 -708
  • 5Mottram PM, Leano R, Marwick TH. Usefulness of B - type natriuretic pep tide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol, 2003;92 (12) : 1434 - 1438
  • 6Adams V, Jiang H, Yu JT,et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerence. J Am Coll Cardlol 1999;33:959 -965
  • 7Wang TJ, Larson MG, Levy D, et al. Plasma natriuretie peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004 ;350:655 - 663
  • 8Baldus S, Mullerleile K, Chumley P, et al. Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemlc cardiomyopathy Radic Biol Med. 2006 ;41 ( 8 ) : 1282 - 1288
  • 9Struthers AD, Donnan PT, Lindsy P, et al : Effect of allopurinal on mortality and hospitalisationa in chronic heart failure:A retrospective cohort study. Heart 2002 ;87:229 - 234
  • 10Shi Y, Evans JE, Rock KL : Molecular identification of a danger signal that alerts the immune system to dying ceils. Nature 2003 ;425 : 516 ~ 521

共引文献1819

同被引文献19

  • 1Kim SY, Guevara JP, Kim KM, et al. Hyperuficemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken), 2010, 62: 170-180.
  • 2Smink PA, Bakker SJL, Laverman GD, et al. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with the cardiovascular protection; a post- hoe analysis of the RENAAL and IDNT trials. J Hypertens, 2012, 30: 1022-1028.
  • 3Daijiro U, lwao O, Kimiyoshi I, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med, 2010, 49: 89-94.
  • 4Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens, 2008, 26: 269-275.
  • 5Yamada T, Fukatsu M, Suzuki S, et al. Elevated serum uric acid predicts impaired fasting glucose and type 2 diabetes only among Japanese women undergoing health checkups. Diabetes Metab, 2011, 37: 252-258.
  • 6Filiopoulos V, Hadjiyannakos D, Vlassopoulas D. New insights into uric acid effects on the progression and prognosis of chronic kidney disease. Renal Failure, 2012, 34: 510-520.
  • 7Lippi G, Targher G, Montagnana M, et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med, 2009, 133: 628-632.
  • 8Felker GM, Alien LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coil Cardiol, 2007, 50: 40-47.
  • 9Lee WS, Kim TY. Relation between red blood cell distribution width and inflammatory biomarkers in rheumatoid arthritis. Arch Pathol Lab Med, 2010, 134: 505-506.
  • 10Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol, 2009, 53: 317-333.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部